Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.（MRTX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · MRTX · 截至 2026年6月9日
活动摘要
买入笔数
5
P-Purchase only
卖出笔数
11
近12个月
买卖比
0.45
Buy/Sell (by trades)
整体情绪
Mirati Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
MRTX 季度内部人买卖趋势
MRTX 内幕交易卖出 · MRTX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
MRTX 高管卖出股份 · MRTX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 23, 2024 | Boxer Capital, LLC other: See remarks | Other | 30,518 | $31 | Form 4 |
| Jan 23, 2024 | Sharp Shalini Director | Other | 4,162 | $241K | Form 4 |
| Jan 23, 2024 | Sharp Shalini Director | Other | 5,252 | — | Form 4 |
| Jan 23, 2024 | Sharp Shalini Director | Other | 6,808 | — | Form 4 |
| Jan 23, 2024 | Cherrington Julie M Director | Other | 4,444 | — | Form 4 |
| Jan 23, 2024 | Cherrington Julie M Director | Other | 6,808 | — | Form 4 |
| Jan 23, 2024 | Davis Aaron I. Director | Other | 43,073 | $2.50M⚡ | Form 4 |
| Jan 23, 2024 | Davis Aaron I. Director | Other | 4,444 | — | Form 4 |
| Jan 23, 2024 | Davis Aaron I. Director | Other | 6,808 | — | Form 4 |
| Jan 23, 2024 | CARTER BRUCE L A Director | Other | 6,021 | $349K | Form 4 |
| Jan 23, 2024 | CARTER BRUCE L A Director | Other | 4,444 | — | Form 4 |
| Jan 23, 2024 | CARTER BRUCE L A Director | Other | 6,808 | — | Form 4 |
| Jan 23, 2024 | Johnson Craig A Director | Other | 6,021 | $349K | Form 4 |
| Jan 23, 2024 | Johnson Craig A Director | Other | 4,444 | — | Form 4 |
| Jan 23, 2024 | Johnson Craig A Director | Other | 6,808 | — | Form 4 |
| Jan 23, 2024 | Hasnain Faheem Director | Other | 8,717 | $506K | Form 4 |
| Jan 23, 2024 | Hasnain Faheem Director | Other | 6,333 | — | Form 4 |
| Jan 23, 2024 | Hasnain Faheem Director | Other | 9,702 | — | Form 4 |
| Jan 23, 2024 | Ondrey Aaron CFO | Other | 1,302 | $76K | Form 4 |
| Jan 23, 2024 | Ondrey Aaron CFO | Other | 21,138 | — | Form 4 |
| Jan 23, 2024 | Ondrey Aaron CFO | Other | 17,021 | — | Form 4 |
| Jan 23, 2024 | Moriarty John B Chief Legal Officer | Other | 675 | $39K | Form 4 |
| Jan 23, 2024 | Moriarty John B Chief Legal Officer | Other | 71,660 | — | Form 4 |
| Jan 23, 2024 | Hickey Benjamin EVP, Chief Commercial Officer | Other | 27,801 | $1.61M⚡ | Form 4 |
| Jan 23, 2024 | Hickey Benjamin EVP, Chief Commercial Officer | Other | 72,206 | — | Form 4 |
Hickey Benjamin
EVP, Chief Commercial Officer
日期
Jan 23
股数
27,801
均价
$58.00
总金额
$1.61M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 MRTX 内幕交易
MRTX 内幕交易
Mirati Therapeutics, Inc.（MRTX）内幕交易数据来源于公司内部人（包括MRTX）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。MRTX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Mirati Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
MRTX 内幕交易 · 5个问题Mirati Therapeutics, Inc.（MRTX）的内部人包括高管和董事，如MRTX等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026